Clinical Efficacy of Docetaxel and Capecitabine in the Treatment of Gastric Cancer after Radical Surgery
Objective To investigate the clinical efficacy of docetaxel and capecitabine on gastric cancer after radical surgery.Methods A total of 60 patients with gastric cancer were selected from January 2021 to June 2022 as the subjects in The First Hospital of Nanping,Fujian Medical University,and all the patients were treated in the Department of Oncology of our hospital and underwent radical gastric cancer surgery.The 60 study patients were divided into the observation group and the control group based on different postoperative chemotherapy regimens.The control group was treated with docetaxel combined with oxaliplatin and 5-fluorouracil chemotherapy regimen at 2~4 weeks after surgery,while the observation group was treated with docetaxel combined with capecitabine chemotherapy regimen at 2~4 weeks after surgery.Tumour control rate,tumour regression and chemotherapy toxicity reaction were compared between the two groups after chemotherapy.Results The tumour control rate of the observation group was 96.67%,which was significantly higher than that of the control group of 70.00%at the end of the course of treatment(P<0.05).The chemotherapy-sensitive rate of the observation group was 93.33%,which was significantly higher than that of the control group of 73.33%at the end of the course of treatment(P<0.05).There was no significant difference in the incidence of hand-foot syndrome,nausea and vomiting,and peripheral neurotoxicity between two groups after chemotherapy(P>0.05).The rate of myelosuppression in the observation group was significantly lower than that in the control group(P<0.05).Conclusion Docetaxel and capecitabine have better efficacy in tumour control after radical surgery for gastric cancer patients,and have higher sensitivity to chemotherapy,which helps to reduce the toxic side effects of myelosuppressive chemotherapy.
DocetaxelCapecitabineRadical Surgery for Gastric CancerChemotherapy Side Effects